46 results about "Sensory nerve" patented technology

The invention discloses a wearable fatigue monitoring and feedback method based on deep learning. The method comprises the steps that a heart rate variability signal, a gamma wave band electroencephalogram signal and body movement posture information of a user are collected in real time; denoising, normalizing and synchronously fusing the acquired multi-mode signals; extracting a fatigue state representation vector in real time by adopting a Mamba linear state space sequence model; estimating a user fatigue index in real time based on a lightweight full-connection neural network decoder and constructing an individual fatigue threshold dynamic model; calculating a phase synchronization index of the electroencephalogram signal in real time; and generating and outputting an individualized 40Hz gamma wave band sensory nerve stimulation feedback signal in real time based on the fatigue index and the phase synchronization index. According to the invention, high-robustness fatigue identification and low-delay feedback adjustment in a complex motion noise environment are realized.

Systems, devices, and methods for stimulating peripheral nerves in the fingers or hand to treat tremor are described. For example, a wearable ring device for delivering electrical stimulation to sensory nerves in a patient's finger can include an annular ring having a plurality of electrodes and a detachable unit having a power source and a pulse generator.

Provided is a portable pruritus treatment device which is capable of achieving a sufficient antipruritic effect in lieu of a drug therapy that causes systemic symptoms, and with which a patient can repeatedly perform radiation at home.　This pruritus treatment device is characterized in having a light beam source for emitting a light beam and a light beam radiation probe for radiating the light beam, and is characterized in that the light beam emitted by the light source is percutaneously radiated from the light beam radiation probe toward sensory nerves that dominate a pruritus occurrence site of the skin or the mucosal epithelium.

Provided is a composition for preparing a medicament for treating diabetic peripheral neuropathy. The pharmaceutical composition comprises cobra venom phospholipase A2, or a combination of cobra venom phospholipase A2 and at least one additional drug for treating diabetic peripheral neuropathy. The diabetic peripheral neuropathy is characterized by a slowdown in motor nerve conduction velocity and / or sensory nerve conduction velocity of a patient, and / or hypoesthesia or loss of sensation in both lower limbs. The pharmaceutical composition can be used to ameliorate the clinical symptoms described above in patients with diabetic peripheral neuropathy, and belongs to the field of biopharmaceuticals.

Provided are a preparation method for and a use of a dorsal root ganglion organoid. In one aspect, a preparation method for a dorsal root ganglion organoid is provided, which comprises: (1) inducing stem cells in a neural stem cell induction medium, to obtain neural stem cells; (2) inducing the neural stem cells in a neural crest cell induction medium, to obtain neural crest cells; (3) inducing the neural crest cells in a sensory neural progenitor cell induction medium, to obtain sensory neural progenitor cells; (4) inducing the sensory neural progenitor cells in an organoid induction medium, to obtain a dorsal root ganglion organoid. In addition, a use of the dorsal root ganglion organoid obtained by said method is also provided, for example, for drug screening or disease research.

To provide a compound which is a local anesthetic and is useful for inducing selective sensory nerve block.SOLUTION: The compound is represented by formula (II).SELECTED DRAWING: None

The sensor nervous system (SNS) comprises an ecosystem where sensors can be deployed such that any sensor from any vendor can be integrated into or removed from the SNS without the need for redesigning the sensor, sensor system, or SNS to accommodate the changes in sensor device count, type, or functionality. The SNS is agnostic to which platform it is deployed upon and can be used for retrofitting and enhancing existing platforms or integrated into new platform designs. Individual sensors are integrated into sensor pods and the sensor pods are, in turn, integrated into the SNS ecosystem.

A wearable electronic device includes an electrode array for percutaneously stimulating sensory nerves that self-govern a body part distal to a wearing location of the wearable electronic device. The transcutaneous stimulation is configured to induce a current or voltage that induces a sensory impression at a region innervated by the sensory nerve and not at the stimulated sensory nerve itself. In one embodiment, the wearable electronic device employs a ring shape that is worn on the proximal phalanx of the index finger. In this configuration, the wearable electronic device may stimulate a portion of a branch extending through the median nerve of the index finger. When the median nerve is stimulated, a user wearing the ring can perceive pressure applied to the fingertip of the user.

Provided herein are compounds that are local anesthetics and useful for inducing selective sensory nerve blockade. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of inducing selective sensory nerve blockade by administering the compounds and / or compositions to a subject.

The invention discloses prevention and treatment of diseases by stimulating TRPV1 + sensory nerves. Specifically, the invention discloses application of a substance for stimulating TRPV1 + sensory nerves in preparation of products for prevention, treatment or adjuvant treatment of inflammatory diseases, autonomic nerve dysfunction diseases or adrenal insufficiency diseases, and application of the substance for stimulating TRPV1 + sensory nerves in preparation of products for inhibiting proinflammatory cytokines and products for promoting anti-inflammatory cytokines. The TRPV1 ion channel agonist disclosed by the invention can obviously and effectively inhibit the expression of numerous proinflammatory cytokines and obviously improve the expression of anti-inflammatory cytokines IL10, so that not only is the physiological status of an inflammatory mouse obviously improved, but also the survival rate of the inflammatory mouse is obviously improved; meanwhile, the spleen function can be adjusted, expression of spleen pro-inflammatory genes is remarkably inhibited, generation of catecholamine is increased, and secretion of cortisol hormones is promoted. The invention has wide clinical application value in prevention and treatment of related diseases.

This disclosure provides compositions and methods for treating sensorineural hearing loss and auditory neuropathy, particularly disease forms associated with otomorphin (OTOE) mutations, using OTOE gene therapy. The disclosure provides various compositions comprising a first nucleic acid vector containing a polynucleotide encoding the N-terminal portion of an OTOE isoform 5 protein and a second nucleic acid vector containing a polynucleotide encoding the C-terminal portion of an OTOE isoform 5 protein. These vectors can be used to increase OTOE expression in subjects, such as human subjects with sensorineural hearing loss.

Provided herein are compounds that are local anesthetics and useful for inducing selective sensory nerve blockade. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of inducing selective sensory nerve blockade by administering the compounds and / or compositions to a subject.

The invention discloses a digital integrated brain injury nerve regulation diagnosis and treatment platform, and relates to the technical field of brain injury diagnosis and treatment, and the technical scheme is characterized in that the platform comprises a multi-mode brain function monitoring module used for collecting brain function data of a brain injury consciousness disorder patient in real time; the multi-sensory nerve regulation and control stimulation module is used for cooperatively applying multi-sensory stimulation to the patient; and the main control and data processing module receives and processes the multi-modal signals transmitted by the multi-modal brain function monitoring module, generates a personalized nerve regulation scheme by extracting brain function characteristics, and controls the multi-sensory nerve regulation stimulation module to execute the personalized nerve regulation scheme at the same time. According to the method, multi-sensory stimulation is cooperatively applied to the patient, the problem of pain points of traditional distributed non-standard stimulation is solved, the core requirement of the patient for multi-channel sensory input awakening is met, meanwhile, a complete closed loop of monitoring-analysis-intervention-feedback is formed, and dynamic evaluation and accurate intervention on the brain function state of the patient with acute brain injury consciousness disorder are achieved.

Provided is stimulation of TRPV1+ and / or TRPA1+ sensory nerves for the prevention and treatment of diseases. Particularly provided is use of a substance for stimulating TRPV1+ and / or TRPA1+ sensory nerves in the prevention or treatment of inflammatory diseases, dysautonomia, or adrenal insufficiency, and in inhibiting the generation of pro-inflammatory cytokines and promoting the generation of anti-inflammatory cytokines. A TRPV1 and / or TRPA1 ion channel agonist can significantly effectively inhibit the expression of numerous pro-inflammatory cytokines and significantly improve the expression of the anti-inflammatory cytokine IL10, significantly improving both the physiological state and the survival rate of mice with inflammation. Moreover, the agonist can adjust spleen function, significantly inhibit the expression of pro-inflammatory genes in the spleen, increase the generation of catecholamine, and promote the secretion of cortisol-like hormones. The agonist has wide clinical application value for the prevention and treatment of related diseases.

The application discloses a kind of sensation nerve quantitative detection method and system based on electroencephalogram characteristics, it is related to electroencephalogram measurement technical field, including: establishing and corresponding detection file of user;Respectively current stimulation module and electroencephalogram detection module are worn in the wrist of user and head;By current stimulation module, current stimulation is gradually applied to user, and gamma wave in the electroencephalogram signal of user is collected in real time by electroencephalogram detection module;Analysis gamma wave in the electroencephalogram signal of user, whether the current intensity that current stimulation module applies to user exceeds the physical stimulation perception threshold of subject is judged;Analysis sensation disorder severity classification.The application has the advantages that: detection is carried out by electroencephalogram signal, does not depend on the subjective feedback of patient, avoids the interference of emotion, psychology and other factors, even if special patient cannot carry out self-perception report, sensation nerve quantitative detection can also be completed by objective physiological response of electroencephalogram.

The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.

Provided herein are compounds that are local anesthetics and useful for inducing selective sensory nerve blockade. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of inducing selective sensory nerve blockade by administering the compounds and / or compositions to a subject.

Provided is a method for inducing human pluripotent stem cells into otic-like neurons, comprising the following steps: S1: inducing human pluripotent stem cells into otic neural precursor cells; S2: purifying the otic neural precursor cells; and S3: expanding and differentiating the otic neural precursor cells into otic-like neurons. Provided is a new and efficient method for differentiating hPSCs into ONs. The method not only enables the induction of pluripotent stem cells into ONs using growth factors, but also optimizes the induction and expansion of ONs by means of the regulation of a signaling pathway and the modification of a culture medium. The technique can not only be applied to the treatment of diseases such as auditory neuropathy, but also provides new treatment strategies for various diseases such as sensory nervous system injuries.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with biallelic missense mutations in otoferlin (OTOE), by way of OTOE gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOE isoform 5 protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOE isoform 5 protein. These vectors can be used to increase the expression of OTOE in a subject, such as a human subject suffering from sensorineural hearing loss.

The invention discloses an implantable intelligent blood pressure adjusting method and system based on a micro-nano ultrasonic device, and relates to the technical field of biomedical engineering.The implantable intelligent blood pressure adjusting method comprises the steps that a lithium niobate piezoelectric micromechanical ultrasonic transducer implanted near the renal door and the renal artery is controlled, and ultrasonic beams with the set center frequency are emitted to the blood vessel wall; echo signals reflected by the front wall and the rear wall of the blood vessel are collected; performing time domain peak detection on the echo signals, calculating the transit time of ultrasonic waves in a blood vessel cavity, calculating the instantaneous diameter of the blood vessel by combining the sound velocity, generating a real-time blood pressure value based on inversion of a blood vessel wall elastic mechanical model, and generating a blood pressure state judgment result; transmitting set intensity focused ultrasound to act on renal door sensory nerves according to a judgment result, and activating sensory pathways to release calcitonin gene-related peptides to induce vascular smooth muscle relaxation so as to reduce blood pressure. The lead-free single crystal lithium niobate piezoelectric micromechanical ultrasonic transducer is introduced, so that the biocompatibility and safety of the implanted device are greatly improved.

The application discloses a nose-sucking type smoking-cessation device and a medicine carrier thereof, which comprises a nose-sucking part and a medicine carrier bin connected to the lower part of the nose-sucking part; wherein one end of the medicine carrier bin close to the nose-sucking part is provided with a releasing end, and the releasing end is connected with a medicine carrier bin clamping end; a medicine transmission channel is formed between the nose-sucking part and the medicine carrier bin. The replaceable medicine carrier is driven by the pressure difference generated by nasal inhalation to transmit the medicine from the medicine carrier bin to the nose-sucking part through the channel, and the trace medicine is used to act on the olfactory sensory nerve of the nasal cavity to achieve the purpose of smoking cessation. The application has the advantages of simple structure, no power supply, no electronic elements, no smoke, no open fire and suitability for various environments.

This application relates to the field of traditional Chinese medicine (TCM) technology, disclosing a TCM compound composition, its preparation method, and its application in treating discogenic low back pain. The TCM compound composition comprises the following components in parts by weight: Astragalus membranaceus 30g, Ligusticum chuanxiong 18g, Angelica sinensis 9g, Rehmannia glutinosa (processed) 18g, Paeonia lactiflora (fried) 18g, Codonopsis pilosula 9g, Bupleurum chinense 9g, Poria cocos 9g, Stephania tetrandra 9g, Aconitum carmichaelii (processed) 9g, and Angelica pubescens 9g. This TCM compound composition improves the metabolism and structural state of multifidus muscle, restores the mechanical stability of spinal segments, reduces the continuous input of abnormal mechanical stimulation from the source, thereby inhibiting the activation of the Piezo1-Netrin-1 axis, reducing vascular and sensory nerve ingrowth, and ultimately resulting in the protection of the cartilaginous endplate structure and improved pain sensitivity.

Disclosed in the present invention is a wearable device for treating or preventing headache, comprising a stimulator and a flexible fixing member connected to the stimulator, wherein the flexible fixing member can fix the stimulator on the wrist, head or upper arm. The wearable device further comprises: a first electrode for targeting wrist nerves in the wrist, the stimulator being configured to provide an electric stimulation to the wrist nerves in the wrist via the first electrode; and a second electrode for targeting frontal nerves in the head and the sensory nerve C-type fibers in the upper arm, the stimulator being configured to provide an electric stimulation to the frontal nerves in the head and the sensory nerve C-type fibers in the upper arm via the second electrode. Since the wearable device can be worn on the wrist, head or upper arm, patients can freely choose a wearing position on the basis of current usage occasions and personal preferences, so as to meet the needs of the patients for use in various occasions, and achieve the convenience of daily carrying, thereby greatly improving the convenience in use of headache treatment devices, and providing users with more options.

The invention discloses an environment sensing bionic robot wolf applied to the field of robot wolves, which comprises a control part and a sensing head mounted on the left side of the upper end of the control part, and can accurately sense extreme weather conditions through the cooperation of a traction arc block, an identification protection assembly and an identification protection system. An active protection mechanism for the sensing cover can be automatically activated under a severe weather condition, so that the negative influence of an extreme environment on sensing recognition is remarkably weakened, the environment sensing precision of the sensing nerve acquisition unit is effectively improved, the task execution reliability of the bionic robot wolf under a complex working condition is ensured, and meanwhile, the service life of the bionic robot wolf is prolonged. Data interconnection is achieved through wireless signals and a central control monitoring platform, an efficient information transmission channel is constructed, the integrity and timeliness of environment recognition data are guaranteed, the comprehensive capacity of the bionic robot wolf in the aspect of multi-source information processing is further enhanced, and finally the comprehensive improvement of the environment adaptability and the function efficiency of the bionic robot wolf is achieved.

The utility model discloses a wearable device for treating or preventing headache, which comprises a stimulator and a flexible fixing piece connected with the stimulator, and the flexible fixing piece can fix the stimulator on a wrist, a head or an upper arm; the first electrode is used for targeting wrist nerves on the wrist, and the stimulator is configured to provide electrical stimulation for the wrist nerves on the wrist through the first electrode; the second electrode is used for targeting frontal nerves of the head or sensory nerve C-type fibers on the upper arms, and the stimulator is configured to provide electrical stimulation for the frontal nerves of the head or the sensory nerve C-type fibers on the upper arms through the second electrode; the wearable device can be worn on the wrist, the head or the upper arm, so that a patient can freely select the wearing position according to the current use occasion and preference, the use requirements of the patient in various use scenarios can be met, the wearable device is convenient to carry daily, the use convenience of the headache treatment instrument is greatly improved, and more choices are provided for a user.

This invention provides the application of berberine II derivatives in the preparation of drugs for treating diabetic foot, belonging to the field of biomedical technology. This invention is the first to discover that berberine II derivatives can significantly improve symptoms such as decreased motor / sensory nerve conduction velocity and loss of pain sensation in diabetic foot model rats, and promote wound healing in the affected foot. Berberine II derivatives hold promise for further development and research as a novel drug for treating diabetic foot.

The invention relates to the technical field of food, and particularly discloses a composition for promoting auditory sense system development and application. The composition is prepared from the following components in parts by mass: 0.1 part of IGF-1 and 1 to 1500 parts of structural triglyceride. A specific amount of IGF-1 is compounded with structural triglyceride, so that the movement speed and average movement distance of the zebrafish after auditory stimulation can be increased, the content of 5-hydroxytryptamine and acetylcholin esterase in the zebrafish is increased, the expression of GABA receptor genes is promoted, and the yield of the zebrafish is increased. By adding important neurotransmitters in an auditory sense system, auditory sense neuron survival, differentiation and synaptic formation are supported, so that the excitability of an auditory sense nerve pathway is adjusted, and the development of the auditory sense system is promoted. The composition can be used for preparing food such as infant formula milk powder, child formula milk powder, liquid milk, infant complementary food, supplements or dietary supplements.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium channel activity (e.g., depolarization-induced calcium influx), and their use as therapeutics for the treatment and / or prevention of CaV3.2 related pain (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) and related conditions.

The invention relates to a preparation method and application of dorsal root ganglion organoid. On one hand, the invention provides the preparation method of the dorsal root ganglion organoid, which comprises the following steps: (1) inducing stem cells in a neural stem cell induction culture medium to obtain neural stem cells; (2) inducing the neural stem cells in a neural crest cell induction culture medium to obtain neural crest cells; (3) inducing the neural crest cells in a sensory nerve progenitor cell induction culture medium to obtain sensory nerve progenitor cells; and (4) inducing the sensory nerve progenitor cells in the organoid induction culture medium to obtain the dorsal root ganglion organoid. Moreover, the invention also provides application of the dorsal root ganglion organoid obtained by the method, for example, the dorsal root ganglion organoid is used for drug screening or disease research.

This invention is in the field of medicinal chemistry. In particular, the invention relates to anew class of small-molecules having a piperazine or piperidine structure which function as either inhibitors of pan-T-type calcium channel activity (e.g., CaV3.1 voltage gated calcium channel activity) (e.g., CaV3.2 voltage gated calcium channel activity) (e.g., CaV3.3 voltage gated calcium channel activity) (e.g., depolarization-induced calcium influx) or specific inhibitors of CaV3.2 voltage gated calcium channel activity, and their use as therapeutics for the treatment and / or prevention of pan-T-type calcium channel related pain (e.g., CaV3.1 related pain) (e.g., CaV3.2 related pain) (e.g., CaV3.3 related pain) (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) (e.g., tonic, neuropathic, and / or inflammatory pain) and related conditions.